Danaher Corporation ( NYSE: DHR ) added ~3% pre-market Thursday after the life sciences company reported better than expected financials for Q3 2022 that its management attributed to the outperformance of all three segments.
Washington, DC-based Danaher ( DHR ) operates three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions.
“Our growth was broad-based across all three segments, a testament to the durability and attractive end-market positioning of the franchises that comprise Danaher,” Chief Executive Rainer Blair noted ahead of the earnings call at 8:00 a.m. ET.
Revenue for the period rose ~6% YoY to ~$7.3B as Diagnostics division generated ~$2.7B with ~9% YoY growth to exceed average analyst estimates based on data compiled by Bloomberg.
Meanwhile, Life Sciences and Environmental & Applied Solutions added ~$3.8B and ~$1.2B with ~4% YoY and ~5% YoY growth in line with Street forecasts.
However, operating margin reached ~26% from ~18% in the prior-year quarter even as operating profit at ~$2.0B fell short of analyst estimates despite ~54% YoY growth.
While gross margin held steady at ~60%, net earnings jumped ~36% to ~$1.6B and operating cash flow for the quarter exceeded Street forecasts to stand at $2.0B.
The company projects its adjusted full year base business core revenue growth to reach a high-single digit percent range and base business core revenue growth to stand at a similar range in the current quarter.
For further details see:
Danaher posts Q3 beat after broad-based growth